Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUNBMA)

Drug Name

MT-1621 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Thymidine kinase 2 deficiency	5C55.1	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Thymidine kinase 2 (Mt-TK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1-[5-(triphenylmethoxy)pentyl]thymine	DMFHBJM	Discovery agent	N.A.	Investigative	[3]
1-[6-(triphenylmethoxy)hexyl]thymine	DM5NVHO	Discovery agent	N.A.	Investigative	[3]
1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine	DMU3VWA	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04581733) A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Modis Therapeutics.
3	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73.